Kristine H Allin1, Stig E Bojesen, Børge G Nordestgaard. 1. Department of Clinical Biochemistry, Herlev Hospital, and The Copenhagen City Heart Study, Bispebjerg Hospital, Copenhagen University Hospital, Denmark.
Abstract
PURPOSE: We tested the hypothesis that baseline plasma levels of C-reactive protein (CRP) are associated with risk of incident cancer in the general population and early death in patients with cancer. PATIENTS AND METHODS: A total of 10,408 individuals from the Danish general population who had CRP measured at baseline were observed for up to 16 years; 1,624 developed cancer, and of these, 998 patients died during follow-up. Follow-up was 100% complete. We excluded individuals with a cancer diagnosis at baseline. RESULTS: Baseline CRP levels more than 3 versus less than 1 mg/L were associated with multifactorially adjusted hazard ratios of 1.3 (95% CI, 1.0 to 1.6) for cancer of any type, 2.2 (95% CI, 1.0 to 4.6) for lung cancer, 1.9 (95% CI, 0.8 to 4.6) for colorectal cancer, and 0.7 (95% CI, 0.4 to 1.4) for breast cancer. Corresponding hazard ratios for the highest versus the lowest quintile of baseline CRP levels were 1.3 (95% CI, 1.0 to 1.6), 2.1 (95% CI, 1.2 to 3.8), 1.7 (95% CI, 0.8 to 3.2), and 0.9 (95% CI, 0.5 to 1.7), respectively. Multifactorially adjusted hazard ratios for early death in patients with cancer were 1.8 (95% CI, 1.2 to 2.7) for CRP more than 3 versus less than 1 mg/L and 1.4 (95% CI, 1.1 to 1.7) for the highest versus the lowest quintile. Elevated CRP levels were associated with early death in patients with cancer having localized disease, but not in those with metastases (interaction; P = .03). CONCLUSION: Elevated levels of CRP in cancer-free individuals are associated with increased risk of cancer of any type, of lung cancer, and possibly of colorectal cancer. Moreover, elevated levels of baseline CRP associate with early death after a diagnosis of any cancer, particularly in patients without metastases.
PURPOSE: We tested the hypothesis that baseline plasma levels of C-reactive protein (CRP) are associated with risk of incident cancer in the general population and early death in patients with cancer. PATIENTS AND METHODS: A total of 10,408 individuals from the Danish general population who had CRP measured at baseline were observed for up to 16 years; 1,624 developed cancer, and of these, 998 patients died during follow-up. Follow-up was 100% complete. We excluded individuals with a cancer diagnosis at baseline. RESULTS: Baseline CRP levels more than 3 versus less than 1 mg/L were associated with multifactorially adjusted hazard ratios of 1.3 (95% CI, 1.0 to 1.6) for cancer of any type, 2.2 (95% CI, 1.0 to 4.6) for lung cancer, 1.9 (95% CI, 0.8 to 4.6) for colorectal cancer, and 0.7 (95% CI, 0.4 to 1.4) for breast cancer. Corresponding hazard ratios for the highest versus the lowest quintile of baseline CRP levels were 1.3 (95% CI, 1.0 to 1.6), 2.1 (95% CI, 1.2 to 3.8), 1.7 (95% CI, 0.8 to 3.2), and 0.9 (95% CI, 0.5 to 1.7), respectively. Multifactorially adjusted hazard ratios for early death in patients with cancer were 1.8 (95% CI, 1.2 to 2.7) for CRP more than 3 versus less than 1 mg/L and 1.4 (95% CI, 1.1 to 1.7) for the highest versus the lowest quintile. Elevated CRP levels were associated with early death in patients with cancer having localized disease, but not in those with metastases (interaction; P = .03). CONCLUSION: Elevated levels of CRP in cancer-free individuals are associated with increased risk of cancer of any type, of lung cancer, and possibly of colorectal cancer. Moreover, elevated levels of baseline CRP associate with early death after a diagnosis of any cancer, particularly in patients without metastases.
Authors: Kasper Broedbaek; Volkert Siersma; Jon T Andersen; Morten Petersen; Shoaib Afzal; Brian Hjelvang; Allan Weimann; Richard D Semba; Luigi Ferrucci; Henrik E Poulsen Journal: Free Radic Res Date: 2011-01-28
Authors: Andrew T Chan; Camelia S Sima; Ann G Zauber; Paul M Ridker; Ernest T Hawk; Monica M Bertagnolli Journal: Cancer Prev Res (Phila) Date: 2011-08
Authors: Corinne E Joshu; Kostantinos K Tsilidis; Sarah B Peskoe; Francis M Giardiello; Paul J Dluzniewski; William G Nelson; Christine A Iacobuzio-Donahue; Elizabeth A Platz Journal: Cancer Causes Control Date: 2014-01-17 Impact factor: 2.506
Authors: Gang Wang; Ni Li; Sheng Chang; Bryan A Bassig; Lanwei Guo; Jiansong Ren; Kai Su; Fang Li; Shuohua Chen; Shouling Wu; Yuhuan Zou; Min Dai; Tongzhang Zheng; Jie He Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-12-09 Impact factor: 4.254
Authors: Joshua Demb; Esther K Wei; Monika Izano; Stephen Kritchevsky; Helen Swede; Anne B Newman; Michael Shlipak; Tomi Akinyemiju; Steven Gregorich; Dejana Braithwaite Journal: J Geriatr Oncol Date: 2018-08-03 Impact factor: 3.599
Authors: Alexandra Masson-Lecomte; Evangelina López de Maturana; Michael E Goddard; Antoni Picornell; Marta Rava; Anna González-Neira; Mirari Márquez; Alfredo Carrato; Adonina Tardon; Josep Lloreta; Montserrat Garcia-Closas; Debra Silverman; Nathaniel Rothman; Manolis Kogevinas; Yves Allory; Stephen J Chanock; Francisco X Real; Núria Malats Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-05-06 Impact factor: 4.254